Teva has now completed its acquisition of Actavis Generics, which includes Medis. As a result of the acquisition, Medis and Teva Industrial Business (Teva IB) will combine their operations under the Medis name. As such, Medis will continue to be your partner in growth, stronger than ever.
The new combined organization provides unparalleled worldwide access to high-quality medicines. The excellent strategic fit between the two companies means an expanded product portfolio and pipeline, both of which create attractive opportunities and value for all our stakeholders.
EXTENSIVE CUSTOMER FOCUS
With the additional benefit of enhanced capabilities in manufacturing, R&D and logistics, Medis believes the acquisition will strengthen its reputation as the partner of choice in third-party generic pharmaceuticals. Our intention is to maintain this dynamic role by continuing to deliver the highest standards of quality and outstanding customer service.